Portfolio News
Sofinnova MD Start
ELSAN partners with MD Start III to accelerate medtech innovation
This collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
Related Strategy
MD StartRelated Deal lead
Anne OsdoitThis collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
June 25, 2020 - PARIS, France -
ELSAN, a leader in the private hospital sector in France, announces a strategic partnership with the Sofinnova MD START III acceleration fund. Through this partnership, ELSAN becomes an investor in the acceleration fund co-created and managed by Sofinnova Partners, a leading European venture capital firm, and offers its healthcare practitioners the means to accelerate the development of their medical device innovations for the benefit of patients.
"We are delighted that ELSAN is joining Sofinnova MD Start III as a community of clinical investigators and experts," commented Anne Osdoit, Partner at Sofinnova Partners.
Related News
Actithera strengthens leadership team and Board as company advances towards clinical development
Bionyra Pharma announces first healthy volunteers dosed in Phase 1 study of BYN-001, a long-acting IL-25 antibody for atopic dermatitis
NodThera changes name to Rezera Inc. and announces Ruvonoflast Phase 3 development program
ProQR announces first participant dosed in Phase 1 study of AX-0811
Rezera announces Ruvonoflast met primary inflammation endpoint and demonstrated favorable safety profile in trial